asentra 50 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - sertralīns - apvalkotā tablete - 50 mg
asentra 100 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - sertralīns - apvalkotā tablete - 100 mg
sertraline accord 100 mg apvalkotās tabletes
accord healthcare b.v., netherlands - sertralīns - apvalkotā tablete - 100 mg
sertralin actavis 50 mg apvalkotās tabletes
teva b.v., netherlands - sertralīns - apvalkotā tablete - 50 mg
progesterone besins 300 mg mīkstās vaginālās kapsulas
besins healthcare ireland limited, ireland - progesterons - vaginālā kapsula, mīkstā - 300 mg
cyclophosphamide accord 500 mg pulveris injekciju/infūziju šķīduma pagatavošanai
accord healthcare b.v., netherlands - ciklofosfamīds - pulveris injekciju/infūziju šķīduma pagatavošanai - 500 mg
cyclophosphamide accord 1000 mg pulveris injekciju/infūziju šķīduma pagatavošanai
accord healthcare b.v., netherlands - ciklofosfamīds - pulveris injekciju/infūziju šķīduma pagatavošanai - 1000 mg
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiski līdzekļi - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
orserdu
stemline therapeutics b.v. - elacestrant - krūts audzējs - endokrīnā terapija - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
torisel
pfizer europe ma eeig - temsirolims - carcinoma, renal cell; lymphoma, mantle-cell - antineoplastiski līdzekļi - nieru šūnu carcinomatorisel ir norādīts pirmās līnijas ārstēšanai pieaugušiem pacientiem ar progresējošu nieru šūnu karcinomas (rsp), kas ir vismaz trīs no sešiem zīlēšana riska faktori. apmetni-šūnu lymphomatorisel ir norādīts ārstēšanai pieaugušiem pacientiem ar relapsed un / vai ugunsizturīgu apvalku-šūnu limfomas (mcl).